Cysteine A Potential Biomarker for Obstructive Sleep Apnea
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/33397 http://dx.doi.org/10.1378/chest.10-0667 |
Resumo: | Objective: Obstructive sleep apnea (OSA) is a risk factor for a number of cardiovascular conditions. Although homocysteine (Hey) and cysteine (Cys) are regarded as cardiovascular risk factors, few studies have analyzed Hey and Cys plasma concentrations in patients with OSA. the aim of this study was to evaluate the role of Hey and Cys in OSA in comparison with subjects without OSA and to determine the possible influence of obesity on these variables.Methods: Patients who submitted to polysomnography studies were recruited to engage in an 8-h fasting period for blood sample withdrawal, physical examination, ECG, and echocardiogram. A subgroup of lean patients with OSA (BMI <25 kg/m(2)) were analyzed to rule out the influence of obesity. Fifteen patients were randomly assigned to participate in a continuous positive airway pressure (CPAP) protocol to assess the influence of OSA treatment on the obtained measurements.Results: A total of 75 patients and 75 control subjects matched for age and sex were analyzed. the Cys plasma levels were higher in patients with OSA compared with control subjects (490.16 +/- 67.00 mu mol/L vs 439.81 +/- 76.12 mu mol/L, respectively, P < .01); however, the Hey plasma levels did not differ between groups. Cys plasma levels were also higher in the OSA lean subgroup when compared with lean control subjects (484.21 +/- 71.99 mu mol/L vs 412.01 +/- 70.73 mu mol/L, respectively, P = .009). There was a significant decrease of Cys plasma levels after 6 months of CPAP effective therapy.Conclusion: Cys is a potential biomarker of OSA in obese and nonobese patients and is reduced after effective OSA treatment. CHEST 2011; 139(2):246-252 |
id |
UFSP_f952e91fceb99dfce483b067669f51fe |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/33397 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Cintra, Fatima [UNIFESP]Tufik, Sergio [UNIFESP]D'Almeida, Vania [UNIFESP]Calegare, Bruno F. A. [UNIFESP]Paola, Angelo Amato Vincenzo de [UNIFESP]Oliveira, Wercules [UNIFESP]Rizzi, Camila [UNIFESP]Roizenblatt, Suely [UNIFESP]Poyares, Dalva [UNIFESP]Universidade Federal de São Paulo (UNIFESP)2016-01-24T14:06:06Z2016-01-24T14:06:06Z2011-02-01Chest. Northbrook: Amer Coll Chest Physicians, v. 139, n. 2, p. 246-252, 2011.0012-3692http://repositorio.unifesp.br/handle/11600/33397http://dx.doi.org/10.1378/chest.10-066710.1378/chest.10-0667WOS:000287773100005Objective: Obstructive sleep apnea (OSA) is a risk factor for a number of cardiovascular conditions. Although homocysteine (Hey) and cysteine (Cys) are regarded as cardiovascular risk factors, few studies have analyzed Hey and Cys plasma concentrations in patients with OSA. the aim of this study was to evaluate the role of Hey and Cys in OSA in comparison with subjects without OSA and to determine the possible influence of obesity on these variables.Methods: Patients who submitted to polysomnography studies were recruited to engage in an 8-h fasting period for blood sample withdrawal, physical examination, ECG, and echocardiogram. A subgroup of lean patients with OSA (BMI <25 kg/m(2)) were analyzed to rule out the influence of obesity. Fifteen patients were randomly assigned to participate in a continuous positive airway pressure (CPAP) protocol to assess the influence of OSA treatment on the obtained measurements.Results: A total of 75 patients and 75 control subjects matched for age and sex were analyzed. the Cys plasma levels were higher in patients with OSA compared with control subjects (490.16 +/- 67.00 mu mol/L vs 439.81 +/- 76.12 mu mol/L, respectively, P < .01); however, the Hey plasma levels did not differ between groups. Cys plasma levels were also higher in the OSA lean subgroup when compared with lean control subjects (484.21 +/- 71.99 mu mol/L vs 412.01 +/- 70.73 mu mol/L, respectively, P = .009). There was a significant decrease of Cys plasma levels after 6 months of CPAP effective therapy.Conclusion: Cys is a potential biomarker of OSA in obese and nonobese patients and is reduced after effective OSA treatment. CHEST 2011; 139(2):246-252Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)AFIP-Associacao Fundo de Incentivo a Psicofarmacologia, São Paulo, BrazilNational Council for Scientific and Technological DevelopmentUniversidade Federal de São Paulo, Dept Psychobiol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Biosci, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Med, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Psychobiol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Biosci, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Med, São Paulo, BrazilFAPESP: 98/14303-3Web of Science246-252engAmer Coll Chest PhysiciansChestCysteine A Potential Biomarker for Obstructive Sleep Apneainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/333972023-02-15 11:04:58.053metadata only accessoai:repositorio.unifesp.br:11600/33397Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:31:42.976951Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Cysteine A Potential Biomarker for Obstructive Sleep Apnea |
title |
Cysteine A Potential Biomarker for Obstructive Sleep Apnea |
spellingShingle |
Cysteine A Potential Biomarker for Obstructive Sleep Apnea Cintra, Fatima [UNIFESP] |
title_short |
Cysteine A Potential Biomarker for Obstructive Sleep Apnea |
title_full |
Cysteine A Potential Biomarker for Obstructive Sleep Apnea |
title_fullStr |
Cysteine A Potential Biomarker for Obstructive Sleep Apnea |
title_full_unstemmed |
Cysteine A Potential Biomarker for Obstructive Sleep Apnea |
title_sort |
Cysteine A Potential Biomarker for Obstructive Sleep Apnea |
author |
Cintra, Fatima [UNIFESP] |
author_facet |
Cintra, Fatima [UNIFESP] Tufik, Sergio [UNIFESP] D'Almeida, Vania [UNIFESP] Calegare, Bruno F. A. [UNIFESP] Paola, Angelo Amato Vincenzo de [UNIFESP] Oliveira, Wercules [UNIFESP] Rizzi, Camila [UNIFESP] Roizenblatt, Suely [UNIFESP] Poyares, Dalva [UNIFESP] |
author_role |
author |
author2 |
Tufik, Sergio [UNIFESP] D'Almeida, Vania [UNIFESP] Calegare, Bruno F. A. [UNIFESP] Paola, Angelo Amato Vincenzo de [UNIFESP] Oliveira, Wercules [UNIFESP] Rizzi, Camila [UNIFESP] Roizenblatt, Suely [UNIFESP] Poyares, Dalva [UNIFESP] |
author2_role |
author author author author author author author author |
dc.contributor.institution.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Cintra, Fatima [UNIFESP] Tufik, Sergio [UNIFESP] D'Almeida, Vania [UNIFESP] Calegare, Bruno F. A. [UNIFESP] Paola, Angelo Amato Vincenzo de [UNIFESP] Oliveira, Wercules [UNIFESP] Rizzi, Camila [UNIFESP] Roizenblatt, Suely [UNIFESP] Poyares, Dalva [UNIFESP] |
description |
Objective: Obstructive sleep apnea (OSA) is a risk factor for a number of cardiovascular conditions. Although homocysteine (Hey) and cysteine (Cys) are regarded as cardiovascular risk factors, few studies have analyzed Hey and Cys plasma concentrations in patients with OSA. the aim of this study was to evaluate the role of Hey and Cys in OSA in comparison with subjects without OSA and to determine the possible influence of obesity on these variables.Methods: Patients who submitted to polysomnography studies were recruited to engage in an 8-h fasting period for blood sample withdrawal, physical examination, ECG, and echocardiogram. A subgroup of lean patients with OSA (BMI <25 kg/m(2)) were analyzed to rule out the influence of obesity. Fifteen patients were randomly assigned to participate in a continuous positive airway pressure (CPAP) protocol to assess the influence of OSA treatment on the obtained measurements.Results: A total of 75 patients and 75 control subjects matched for age and sex were analyzed. the Cys plasma levels were higher in patients with OSA compared with control subjects (490.16 +/- 67.00 mu mol/L vs 439.81 +/- 76.12 mu mol/L, respectively, P < .01); however, the Hey plasma levels did not differ between groups. Cys plasma levels were also higher in the OSA lean subgroup when compared with lean control subjects (484.21 +/- 71.99 mu mol/L vs 412.01 +/- 70.73 mu mol/L, respectively, P = .009). There was a significant decrease of Cys plasma levels after 6 months of CPAP effective therapy.Conclusion: Cys is a potential biomarker of OSA in obese and nonobese patients and is reduced after effective OSA treatment. CHEST 2011; 139(2):246-252 |
publishDate |
2011 |
dc.date.issued.fl_str_mv |
2011-02-01 |
dc.date.accessioned.fl_str_mv |
2016-01-24T14:06:06Z |
dc.date.available.fl_str_mv |
2016-01-24T14:06:06Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Chest. Northbrook: Amer Coll Chest Physicians, v. 139, n. 2, p. 246-252, 2011. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/33397 http://dx.doi.org/10.1378/chest.10-0667 |
dc.identifier.issn.none.fl_str_mv |
0012-3692 |
dc.identifier.doi.none.fl_str_mv |
10.1378/chest.10-0667 |
dc.identifier.wos.none.fl_str_mv |
WOS:000287773100005 |
identifier_str_mv |
Chest. Northbrook: Amer Coll Chest Physicians, v. 139, n. 2, p. 246-252, 2011. 0012-3692 10.1378/chest.10-0667 WOS:000287773100005 |
url |
http://repositorio.unifesp.br/handle/11600/33397 http://dx.doi.org/10.1378/chest.10-0667 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Chest |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
246-252 |
dc.publisher.none.fl_str_mv |
Amer Coll Chest Physicians |
publisher.none.fl_str_mv |
Amer Coll Chest Physicians |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1783460303050113024 |